Prolonged-release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia: a randomized clinical trial - the SMART trial protocol
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Prolonged-release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia: a randomized clinical trial - the SMART trial protocol. / Baandrup, Lone; Fagerlund, Birgitte; Jennum, Poul; Lublin, Henrik; Hansen, Jane L; Winkel, Per; Gluud, Christian Nyfeldt; Oranje, Bob; Glenthoj, Birte Y.
In: B M C Psychiatry, Vol. 11, 2011, p. 160.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Prolonged-release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia: a randomized clinical trial - the SMART trial protocol
AU - Baandrup, Lone
AU - Fagerlund, Birgitte
AU - Jennum, Poul
AU - Lublin, Henrik
AU - Hansen, Jane L
AU - Winkel, Per
AU - Gluud, Christian Nyfeldt
AU - Oranje, Bob
AU - Glenthoj, Birte Y
PY - 2011
Y1 - 2011
N2 - Treatment of schizophrenia frequently includes prolonged benzodiazepine administration despite a lack of evidence of its use. It is often difficult to discontinue benzodiazepines because of the development of dependence. We aim to assess if melatonin can facilitate the withdrawal of prolonged benzodiazepine administration in patients with schizophrenia. Furthermore, we aim to investigate the association of benzodiazepine dose reduction with the following clinically important variables: sleep, psychophysiology, cognition, social function, and quality of life.
AB - Treatment of schizophrenia frequently includes prolonged benzodiazepine administration despite a lack of evidence of its use. It is often difficult to discontinue benzodiazepines because of the development of dependence. We aim to assess if melatonin can facilitate the withdrawal of prolonged benzodiazepine administration in patients with schizophrenia. Furthermore, we aim to investigate the association of benzodiazepine dose reduction with the following clinically important variables: sleep, psychophysiology, cognition, social function, and quality of life.
U2 - http://dx.doi.org/10.1186/1471-244X-11-160
DO - http://dx.doi.org/10.1186/1471-244X-11-160
M3 - Journal article
VL - 11
SP - 160
JO - B M C Psychiatry
JF - B M C Psychiatry
SN - 1471-244X
ER -
ID: 40156269